Septerna, Inc.
SEPN evidence brief
What we can confirm
- BioSniper Score:
- 4.5 / 10
- Market Cap:
- $1.77B
- Lead Asset:
- sep-479 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for SEPN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SEPN
Septerna, Inc. (SEPN) is a clinical-stage biotechnology company focused on oral small molecule GPCR-targeted drug discovery, with lead programs in PTH1R agonism and MRGPRX2 negative allosteric modulation.
Key risk: Operating losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.77B
Cash Runway
—
Lead Asset
sep-479 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Septerna, Inc..
Septerna, Inc. (SEPN) is a clinical-stage biotechnology company focused on oral small molecule GPCR-targeted drug discovery, with lead programs in PTH1R agonism and MRGPRX2 negative allosteric modulation.
- Cash & equivalents of $84.7M as of 2026-06-30 [sec].
- Total revenue of $26.7M and net income of -$13.0M as of 2026-06-30 [sec].
- Phase 1 clinical trial ongoing for SEP-479 (oral small molecule PTH1R agonist); SAD/MAD data expected Q1 2027 [news · 2026-08-10].
- Phase 1 data for SEP-631 (MRGPRX2 NAM) in healthy volunteers reported; Phase 2b in CSU previously planned but now under evaluation based on emerging field data [sec_mda · as of 2026-08-10].
- Cash position of $516.5M as of 2026-08-10 expected to support operating plans at least into 2029 [news · 2026-08-10].
What works
- Cash runway of $516.5M as of 2026-08-10 expected to fund operations at least into 2029, providing multi-year financial visibility [news · 2026-08-10].
- SEP-479 observed terminal half-life of ~3-4 days supports once-daily dosing, a favorable pharmacokinetic profile [sec_mda · as of 2026-08-10].
- Company has a deep portfolio of wholly-owned and partnered GPCR-targeted programs with novel mechanistic approaches [sec_mda · as of 2026-08-10].
What to weigh
- Company has incurred significant operating losses since inception (except 2023) and expects to continue net losses for the foreseeable future [sec_mda · as of 2026-08-10].
- Phase 2b trial for SEP-631 in CSU is now under strategic re-evaluation based on emerging field data, creating pipeline uncertainty [sec_mda · as of 2026-08-10].
- Revenue to date has been generated solely from research services; no product sales revenue yet [sec_mda · as of 2026-05-11].
- Future capital requirements are uncertain due to numerous risks in drug development and commercialization [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Cash position supports operations into 2029
“Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029”
News · August 10, 2026
SEP-479 half-life supports once-daily dosing
“observed terminal half-life of SEP-479 is approximately three to four days, which we anticipate will support once-daily dosing”
SEC MD&A · August 10, 2026
Company expects continued net losses
“We expect to continue to incur net losses for the foreseeable future”
SEC MD&A · August 10, 2026
SEP-631 Phase 2b plan under evaluation
“Based on emerging clinical data in the MRGPRX2 field, in lieu of a Phase 2b clinical trial in CSU, we are now e”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2025-07-15 · Phase 1 start for SEP-631 — A Phase 1, double-blind, randomized, placebo-controlled SAD/MAD study in healthy volunteers to evaluate safety, tolerability, PK, PD, and food effect.
- 2026-03-04 · Phase 1 start for SEP-479 — A Phase 1 SAD/MAD study in healthy adult participants to evaluate safety, tolerability, PK, and PD.
Risks & what to watch (4)›
Key risks
- Operating losses — Company has incurred significant operating losses since inception (except 2023) and expects continued net losses [sec_mda · as of 2026-08-10].
- Pipeline uncertainty — SEP-631 Phase 2b in CSU under strategic re-evaluation due to emerging field data, creating pipeline risk [sec_mda · as of 2026-08-10].
- No product revenue — Revenue to date solely from research services; no commercial product sales [sec_mda · as of 2026-05-11].
- Capital requirement uncertainty — Future funding needs depend on many uncertain factors including trial outcomes and regulatory approvals [sec_mda · as of 2026-08-10].
What to watch
- Phase 1 SAD/MAD data for SEP-479 expected in Q1 2027 [news · 2026-08-10].
- Strategic update on SEP-631 Phase 2b development path following emerging MRGPRX2 field data [sec_mda · as of 2026-08-10].
- Cash runway updates as operating plans extend into 2029 [news · 2026-08-10].
- Any new partnership or pipeline program disclosures from GPCR platform [sec_mda · as of 2026-08-10].
Sources: Catalysts · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Septerna, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Septerna, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.47 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
0 buys · 18 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 9.4%
- Days to cover
- 8.8
- Shares short
- 2,457,303
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SEPN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Septerna, Inc.?
Septerna, Inc. (SEPN) is a clinical-stage biotechnology company focused on oral small molecule GPCR-targeted drug discovery, with lead programs in PTH1R agonism and MRGPRX2 negative allosteric modulation.
What is Septerna, Inc.'s lead drug candidate?
Septerna, Inc.'s most advanced tracked candidate is sep-479 (Phase 1) for Healthy Volunteers.
Who is the CEO of Septerna, Inc.?
Dr. Jeffrey T. Finer M.D., Ph.D. is the chief executive officer of Septerna, Inc. (SEPN).
Where is Septerna, Inc. headquartered?
Septerna, Inc. (SEPN) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Septerna, Inc. focus on?
Septerna, Inc. develops therapies across Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.